By Fineline Cube 
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free iterative rabies vaccine has been accepted for review by the National Medical Products Administration (NMPA). This follows the company’s receipt of a Drug Manufacturing License for the product last month, marking a significant step toward potential global approval.
Vaccine Innovation
The serum-free rabies vaccine represents a novel approach to combating rabies, a disease for which post-exposure prevention is critical due to the lack of effective treatment options. Current mainstream vaccines, including Vero cell and human diploid cell rabies vaccines, rely on serum. AIM Vaccine’s product aims to address this gap with an innovative, serum-free formulation.
Market Potential
With rabies prevention being a global health priority, AIM Vaccine’s product has the potential to become the first of its kind approved worldwide. This development underscores the company’s commitment to advancing vaccine technology and improving public health outcomes.-Fineline Info & Tech